Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-11-05

Clinical Trial Update: Safety and Efficacy of Diacerein 1% Ointment for Subjects With Epidermolysis Bullosa Simplex (EBS) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of 1% diacerein ointment for epidermolysis bullosa simplex was terminated; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Diacerein 1% ointment (diacerein)

Snippet

Sponsor: Castle Creek Pharmaceuticals, LLC | Conditions: Epidermolysis Bullosa Simplex | Phase 2 | Status: TERMINATED | Results posted: 2019-11-05